Legal News, In Brief: FDA Opposes Otsuka Suit; Apotex Can Challenge Benicar Patent
Executive Summary
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.
You may also be interested in...
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.